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Abstract
Proinflammatory cytokines secreted from adipose tissue contribute to the morbidity associated with obesity. IL-1a is one of
the proinflammatory cytokines; however, it has not been clarified whether IL-1a may also cause obesity. In this study, we
investigated whether polymorphisms in IL-1a contribute to human obesity. A total of 260 obese subjects were genotyped
for IL-1a C-889T (rs1800587) and IL-1a G+4845T (rs17561). Analyses of genotype distributions revealed that both IL-1a
polymorphisms C-889T (rs1800587) and G+4845T (rs17561) were associated with an increase in body mass index in obese
healthy women. In addition, the effect of rs1800587 on the transcriptional activity of IL-1a was explored in pre-adipocyte
3T3-L1 cells. Significant difference was found between the rs1800587 polymorphism in the regulatory region of the IL-1a
gene and transcriptional activity. We extended these observations in vivo to a high-fat diet-induced obese mouse model
and in vitro to pre-adipocyte 3T3-L1 cells. IL-1a levels were dramatically augmented in obese mice, and triglyceride was
increased 12 hours after IL-1a injection. Taken together, IL-1a treatment regulated the differentiation of preadipocytes. IL-
1a C-889T (rs1800587) is a functional polymorphism of IL-1a associated with obesity. IL-1a may have a critical function in
the development of obesity.
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Introduction
Worldwide, more than one billion adults are overweight or
obese, and there in no sign that the rapid increase in obesity seen
over the past two decades is abating. Obesity is recognized as a
major risk factor for insulin resistance, and both of these conditions
predict the development of type 2 diabetes mellitus and
cardiovascular disease [1]. One emerging feature of obesity is
the linkage between obesity and chronic, low-grade inflammation
characterized by increased cytokine and chemokine production
and acute-phase inflammatory signaling in adipose tissue [2,3]. In
fact, inflammatory markers, such as C-reactive protein (CRP) and
interleukin (IL)-6, are increased in obese individuals compared
with lean subjects, although not to the same extent observed in
classic inflammatory conditions [4,5].
White adipose tissue (WAT) is characterized by the ability to
produce and release a variety of proinflammatory adipokines such
as leptin, IL-1b, IL-6, IL-8, tumor necrosis factor (TNF)-a,
monocyte chemoattractant protein-1, and macrophage migration
inhibitory factor, all of which have been linked to insulin resistance
[3]. IL-1 is also one of the major proinflammatory cytokines. It
induces fever, synthesis of hepatic acute phase proteins, and the
release of neutrophils as a mediator of acute inflammatory
responses together with some other cytokines [6]. IL-1 is produced
and secreted by a variety of cells including macrophages/
monocytes, endothelial cells, vascular smooth muscle cells, and
hepatocytes [7–9]. Dinarello et al. [10] have reported that the
production of IL-1 is increased in diabetic patients as well as in
patients with rheumatoid arthritis or with cancers, suggesting that
IL-1 may play a role in the pathogenesis of diabetes mellitus. Di
Renzo et al. [11] demonstrated higher levels of IL-1 in obese
subjects. Raymond et al. [12] also reported that IL-1 a production
by cultured peripheral blood mononuclear cells from the obese
group was significantly elevated in comparison to the control
group. However, it remains unclear whether or how IL-1 affects
obesity.
The IL-1 gene family consists of two major agonistic molecules,
namely, IL-1a and IL-1b, and one antagonistic cytokine, the IL-1
receptor antagonist (IL-1Ra) [7]. Both IL-1a and IL-1b are
produced by lymphocytes or monocytes in the loci of inflamma-
tion. Only a few studies have examined the role of IL-1a as a
mediator for cellular insulin resistance [6] in sharp contrast to a
number of reports on IL-1b [13,14].
Most of the genes coding for the IL-1 family of proteins and
clustered on the 2q12-q21 locus (IL-1a, IL-1b, and IL-1Ra) are
polymorphic in multiple loci [15]. A single nucleotide polymor-
phism (SNP) of the IL-1a gene was located at position -889 in the
59-flanking region and the other was found at position +4845.
Dominici et al. [16] reported that lipopolysaccharide-stimulated
mononuclear cells from rs1800587 TT carriers showed an increase
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promoter activity is higher in those individuals showing the TT –
889 genotype over the CC –889 genotype. However Kawaguchi
et al. [17] reported that significant differences in luciferase activity
were not detected between C and T at –889 in systemic sclerosis
fibroblasts, while the SNP at +4845 contributed to the processing
of pre-IL1a in human skin fibroblasts.
Obesity is defined by body mass index (BMI) and further
evaluated in terms of fat distribution via the waist-to-hip ratio
(WHR) and total cardiovascular risk factors [18]. BMI is closely
related to both percentage of body fat (PBF) and total body fat.
Here, we investigated whether polymorphisms in IL-1a contribute
to BMI in humans. We also hypothesized that the increased/
decreased expression of IL-1a as a consequence of IL-1a C-889T
(rs1800587) and IL-1a G+4845T (rs17561) polymorphisms could
be a factor in obesity. We further extended this observation in vivo
to a high-fat diet (HFD)-induced obese mouse model and in vitro
to pre-adipocyte 3T3-L1 cells.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all participants.
The study was approved by the ethical committee of the Kyung
Hee Oriental Medical Hospital. Some of the patients have been
the subject of earlier report [19].
Mouse care and experimental procedures were performed
under approval of the Kyung Hee University Institutional Animal
Care and Use Committee (approval ID KHUASP(SE)-09-031)
and were in compliance with the national and international laws
for the protection and welfare of animals.
Subjects
The subjects were recruited consecutively from an obesity clinic
at a hospital from January 2000 to December 2003 into an
ongoing project to investigate candidate genes for obesity among
the Korean population. All were nonsmokers and had no evidence
of cancer, liver, renal, hematological disease or other metabolic
disorders other than obesity. A total of 260 women met all of the
study criteria and were enrolled in the study. Ages and BMI
ranged between 18 and 62 years and between 19.2 and 54.7 kg/
m
2, respectively. To obtain a better separation between pheno-
types, the participants were divided into four BMI groups
according to WHO definitions with minor modifications: lean
(BMI ,25 kg/m
2), overweight I (BMI 25–26 kg/m
2), overweight
II (BMI 27–29 kg/m
2) and obese (BMI $30 kg/m
2).
Phenotype measurements
Height (in cm) and weight (in kg) were measured to calculate the
BMI as weight (kg)/height (m) squared. Waist circumference
(measured at the narrowest point superior to the hip) was divided
by the circumference of the hip (measured at its greatest gluteal
protuberance) to obtain the WHR. Fat mass was determined by
dual-energy X-ray absorptiometry.
Genotype Determination
Genomic DNA was extracted from whole blood using Exgene
Blood SV kit (GeneAll Biotechnology, Seoul, Republic of Korea).
Genotyping for the IL-1a C–889T (rs1800587) was conducted
essentially according to previous studies [20] with small modifi-
cations. The IL-1a G+4845T (rs17561) was amplified using the
primers 59-ATG GTT TTA GAA ATC ATC AAG CCT AGG
GCA-39 (forward) and 59-ATT GAA AGG AGG GGA GGA
TGA CAG AAA TGT-39(reverse). The PCR products were
digested with Fnu 4H1 (New England Biolabs, Ipswich, MA) [21].
Reagents for Animal Experiments
ELISA capture and detection antibody and recombinant
(standard) were purchased from R&D Systems (Minneapolis,
Minnesota, USA). Dulbecco’s Modified Eagle’s Medium (DMEM),
lipopolysaccharide (LPS), 3-isobutyl-1-methylxanthine (IBMX),
insulin, and dexamethasone acetate were purchased from Sigma
(St. Louis, MO). Western antibodies were obtained from Santa
CruzBiotechnology,Inc.(Santacruz,CA).Fetalbovineserum(FBS)
and other tissue culture reagents were purchased from Gibco BRL
(Grand Island, NY).
IL-1a CC/TT Construct and Transfections
Luciferase reporter plasmid pGL3-Basic (Promega) was used in a
reporter gene assay to examine IL-1a promoter activity. A fragment
of 1,432 bp covering the IL-1a 59-flanking sequence (nucleotide
21351 to +81) was amplified from genomic DNA containing either
a C or T nucleotide at position –889 using the following primers:
forward 59-GGG GTA CCA GGT CTA TGA CCA GGA GAA
TT-39 and reverse 59-CCA AGC TTT AAT AGC CAG AGA TGT
GAG G-39 (the KpnI and HindIII restriction sites are italicized). The
1,432 bp products were then inserted (KpnIa n dHindIII sites) into
the pGL3-Basic vector [16]. All constructs were fully sequenced
(LabFrontier Co. Ltd., Ehwa University, Seoul, Republic of Korea)
before use in transfection experiments. The pGL3 constructs were
transiently transfected into the 3T3-L1 cell line (American Type
Culture Collection). Cells were transiently transfected using cationic
liposomes (Transfast
TM Transfection Reagent, Promega). The cells
were co-transfected with 2 mg of construct DNA and 1.2 mgo ft h e
b-galactosidase plasmid DNA (pSV-b-gal, Promega). For each cell
extract, luciferase activity assays were performed in triplicate using
the standard protocol (Luciferase Assay System, Promega), and light
was measured with a luminometer (VICTOR Light, Perkin Elmer).
Animals
Four-week-old C57BL/6J male mice were purchased from the
Daehan Biolink Co., (Daejeon, South Korea). The animals were
maintained at the college of Oriental Medicine, Kyung Hee
University.
IL-1a Administration
Eight-week-old C57BL/6J male mice were given an intraper-
itoneal (IP) injection of recombinant IL-1a. IL-1a was diluted to
the desired concentration with normal saline. IL-1a (10 mg/kg
body weight) or vehicle (normal saline) was administered IP
respectively. Livers and blood samples were collected 0, 4, 12, and
24 hours after IL-1a or vehicle injection and immediately frozen
in a deep freezer.
Lipid Analysis
Serum was separated immediately after blood sampling by
centrifugation at 10,0006 g for 15 min. Lipids were extracted
from the livers by the method of Folch et al. [22]. Levels of total
cholesterol, triglyceride, and LDL cholesterol were determined
using the colorimetric enzymatic method, using an autoanalyzer
(Hitachi 747; Hitachi, Japan).
Cell Culture and Treatment
3T3-L1 fibroblasts were grown in DMEM plus 10% calf serum
and plated for final differentiation in DMEM plus 10% FBS. Two
days after reaching confluence, the medium was changed to the
IL-1a Functional Variant and Obesity
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sone (0.25 mM), and insulin (10 mg/ml). After 2 days, the cell
culture medium was changed to DMEM containing 10 mg/ml
insulin and 10% FBS. The medium was replaced again with fresh
DMEM containing 10% FBS after 2 days. The cells were treated
with various concentrations of recombinant IL-1a during the
differentiation induction phase (from day 0 to day 8). Cells and
medium were collected 8 days after the initiation of differentiation.
Oil Red O Staining
The 3T3-L1 cells were washed twice with phosphate-buffered
saline (PBS) and were then fixed in 10% formaldehyde in PBS for
1 h. After washing with 60% isopropanol, the cells were stained
with Oil Red O solution for 30 min at room temperature. The
cells were washed with water four times to remove the unbound
dye and were then photographed. To determine the extent of
adipose conversion, 1 ml of isopropanol was added to the stained
culture plates. The extracted dye was collected, and its optical
density was measured at 500 nm using an automated microplate
ELISA reader.
RNA Isolation and Real-time PCR
Total RNA was extracted from culture cell and adipose tissue
samples using a GeneAll
R RiboEx Total RNA extraction kit
(GeneAll Biotechnology, Seoul, Republic of Korea) and QIAzol
RNA extraction kit (Qiagen, USA). Real-time PCR was run on an
Applied Biosystems StepOne Thermal Cycler with a 48-well
reaction plate. A probe for each gene was designed with the
Primer Express 3.0 program (Applied Biosystems, Foster City, CA,
USA) with a 59-FAM and 39-TAMRA modification in addition to
forward and reverse primers. Data were analyzed with StepOne
software 2.0 (Applied Biosystems, Foster City, CA, USA).
Adipokine Assay
The amounts of IL-1a, IL-6, and adiponectin were measured
using standard kits (R&D systems, Inc., Minneapolis, MN, USA).
The ELISA was devised by coating 96-well plates of murine
monoclonal antibody with specificity for IL-1a, IL-6, and
adiponectin. Color development was measured at 405 nm using
an automated microplate ELISA reader.
Statistical Analysis
Statistical analyses were performed by one-way analysis of
variance (ANOVA) with Tukey, and Duncan post-hoc test to
express the difference between groups. Data are presented as the
mean 6 standard deviations (SD). The significance of the genotype
differences between groups was tested by x
2. Odds ratios were
determined by the Mantel-Haenszel method. All statistical analyses
were performed using SPSS v13 (SPSS Inc, Chicago, Illinois, USA).
P,0.05 was considered statistically significant.
Results
Clinical Characteristics of Human Subjects
Anthropometric, biochemical, and clinical characteristics of
subjects are summarized in Table 1. As expected, total cholesterol,
triglyceride, fat mass, PBF, and WHR increased in proportion to
BMI values.
Association between IL-1 a Polymorphism and BMI in
Human Obese Patients
The genotype frequencies of IL-1a C-889T (rs1800587) and IL-
1a G+4845T (rs17561) were in the Hardy-Weinberg equilibrium.
To evaluate the association between the IL-1a polymorphisms and
Table 1. Characteristics of female subjects (n=260).
BMI (kg/m
2)
,25 25–26 27–29 $30
Weight
* (kg) 61.5613.8 64.464.6 71.065.9 84.8613.4
Height
* (cm) 161.165.1 158.665.9 158.565.6 161.265.6
Total cholesterol
*
(mg/dl)
168.2626.9 181.3640.3 179.1634.7 189.8640.7
Triglyceride
* (mg/dl) 79.8635.2 105.6699.5 109.2670.7 131.86116.7
Fat mass
* (kg) 20.162.1 23.362.5 26.663.2 36.268.2
PBF
* (%) 33.662.3 36.162.9 36.965.2 41.964.4
WHR
* 0.8560.03 0.8960.02 0.9260.04 0.9960.07
A total of 260 female subjects (mean age=29.3610.19) were included. Values
are means 6 SD. Abbreviations used: BMI, body mass index; PBF, percentage of
body fat; WHR, ratio of waist-to-hip circumstance.
*Oneway ANOVA, P,0.05.
doi:10.1371/journal.pone.0029524.t001
Table 2. Frequencies for IL-1a genotypes according to BMI in
females (n=260).
BMI (kg/m
2) P
a
,25,
n( % )
25–26,
n( % )
27–29,
n( % )
$30,
n( % )
IL-1a C-889T
(rs1800587)
CC 39 (68.4) 47 (81.0) 71 (92.2) 55 (80.9) 0.003
CT 18 (31.6) 9 (15.5) 6 (7.8) 13 (19.1)
TT 0(0) 2 (3.4) 0 (0) 0 (0)
IL-1a G+4845T
(rs17561)
GG 38 (67.9) 47 (81.0) 70 (90.9) 56 (81.2) 0.004
GT 18 (32.1) 9 (15.5) 7 (9.1) 13 (18.8)
T T 0( 0 ) 2( 3 . 4 ) 0( 0 ) 0( 0 )
rs1800587: rs17561 haplotype
o copies T:T 39 (68.4) 47 (81.0) 70 (90.9) 55 (80.9) 0.013
1 or 2 copies T:T 18 (31.6) 11 (19.0) 7 (9.1)
b 13 (19.1)
BMI, body mass index; OR, odds ratio; CI, confidence interval.
aBy x
2 test (two-sided);
bBy Mantel-Haenszel method; women with BMI ,25 kg/m
2 were the reference
in this analysis: P=0.002, OR=0.217, CI 0.08–0.56.
doi:10.1371/journal.pone.0029524.t002
Table 3. Plasma IL-1a and CRP concentrations in the four BMI
subgroups.
BMI (kg/m
2)I L - 1 a (pg/ml) P
a CRP (ng/ml) P
a
,25 7.6560.55 - 0.7060.54 -
25–26 7.0260.59 0.174 3.0460.07 ,0.001
27–29 8.3961.10 0.064 6.1761.05 ,0.001
$30 7.8660.62 0.454 6.7162.10 ,0.001
BMI, body mass index. Values are means 6 SD.
aBy t test; women with BMI ,25 kg/m
2 were the reference in this analysis.
doi:10.1371/journal.pone.0029524.t003
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The distributions of CC, CT, and TT genotypes of IL-1a C-889T
(rs1800587) and the distributions of GG, GT, and TT genotypes of
IL-1a G+4845T (rs17561) in the study subjects are shown in
Table 2. The frequency of rs1800587 CT+TT genotypes was lower
in a subgroup with BMI 27–29 kg/m
2 than in a subgroup with a
BMI of less than 25 kg/m
2 (odds ratio, OR=0.183, confidence
interval, CI=0.07–0.50, P=0.001). In addition, the GT+TT
genotype frequency of rs17561 polymorphism was also lower in
the BMI 27–29 kg/m
2 subgroup than in lean women (BMI
,25 kg/m
2) (OR=0.211, CI=0.08–0.55, P=0.001). To further
investigate the significant associations between T carriers of IL-1a
rs1800587 and rs17561 with BMI, haplotype analysis was also
performed. The frequency of carriers with one or two copies of the
rs1800587:rs17561 T:T haplotype was significantly lower in a
subgroup with BMI 27–29 kg/m
2 than in lean women (BMI
,25 kg/m
2) (OR=0.217, CI=0.08–0.56, P=0.002). In addition,
we evaluated whether the IL-1a polymorphisms affect other
parameters such as WHR, or PBF. As a result, WHRwas associated
with the IL-1a polymorphisms (rs1800587 and rs17561), but not
PBF (Table S1 and S2). The frequency of carriers with one or two
copies of the rs1800587:rs17561 T:T haplotype was significantly
lowerinasubgroupwith WHRgreaterthanorequalto0.91thanin
women with WHR less than 0.90 (P=0.006) (Table S2).
IL-1a Levels in Human Obese Patients
To investigate whether the observed association has any
physiological (pathophysiological) relevance, plasma IL-1a and
CRP concentrations were measured in the four subgroups. From
the 260 subjects, a subset of 30 subjects was recalled for plasma IL-
1a and CRP measurements (BMI ,25 kg/m
2, n=11; BMI 25–
26 kg/m
2, n=2; BMI 27–29 kg/m
2, n=10; BMI $30 kg/m
2,
n=7).An increase wasfound for circulatingIL-1a concentrationsin
a subgroup with a BMI of 27–29 kg/m
2 (8.3961.10 pg/ml)
compared to a subgroup with a BMI lower than 25 kg/m
2
(7.6560.55 pg/ml), although the statistical significance was mar-
ginal (P=0.06). Furthermore, plasma CRP concentrations were
measured in the four subgroups because IL-1a, IL-6, and TNF-a
primarily regulate the production of CRP by the liver. As expected,
a significant increase was found for plasma CRP concentrations in
overweight and obese groups with a BMI higher than 25 kg/m
2
comparedtoasubgroupwithaBMIlowerthan25 kg/m
2(Table3).
Figure 1. Effect of IL-1a CC or TT at position –889 on luciferase reporter activity. (A) Schematic representation of the 59-flanking region of
the IL-1a gene showing the major transcription start site and the putative transcription factor binding sites. NF-kB=nuclear factor-kB; AP=activator
protein; GRE=glucocorticoid response element. (B) The reporter plasmids containing a fragment of 1,432 bp covering the IL-1a 59-flanking
(nucleotide 21351 to +81) was transfected into 3T3-L1 cells and measured after 48 h. For an assessment of the transfection efficiency, cells were co-
transfected with pSV-b-gal, and the luciferase activity was expressed relative to the pGL3-Basic vector and normalized to the b-galactosidase activity.
Data are the mean 6 SE of the results from three or more experiments conducted in triplicate.
doi:10.1371/journal.pone.0029524.g001
Figure 2. Levels of serum IL-1a in high-fat diet-induced obese
mouse model. IL-1a levels were determined by ELISA method.
Experiments were performed in duplicate, and values represent means
6 S.E.M. (n=10).
doi:10.1371/journal.pone.0029524.g002
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Adipocytes
To examine whether the –889C/T polymorphism in the
regulatory region of the IL-1a gene is important for transcriptional
activity,transcription levelsfromthree reportergeneconstructs were
compared in 3T3-L1 adipocytes. The first construct was a negative
control that contained a promoter-less luciferase reporter gene. The
second and third constructs contained a 1,432 bp fragment covering
the IL-1a 59-flanking (nucleotide 21351 to +81), where one
construct had a C nucleotide at position –889 of this fragment,
and the other construct contained a T nucleotide at position –889
(Fig. 1A). The CC construct produced a 2.9-fold higher level of
luciferase activity than the TT construct (P=0.004) (Fig. 1B).
IL-1a Levels in Obese Mice and Exogenous IL-1a
Administration
To examine whether IL-1a is correlated with obesity, the levels
from serum of HFD-induced obese mice were determined. IL-1a
levels were higher in obese mice than in lean mice (P=0.001)
(Fig. 2). Also, we wished to test the effects of exogenous IL-1a
administration to mice on lipids levels. IL-1a (10 mg/kg body
weight) or vehicle (normal saline) was administered IP respectively.
At 0, 4, 12, and 24 hours after IL-1a or vehicle injection, blood
levels of total cholesterol (TC), triglyceride (TG), low-density
lipoprotein (LDL) cholesterol, and TG from the livers were
measured (Fig. 3). At 12 hours after IL-1a injection, the TG level
in serum was significantly increased (Fig. 3C).
IL-1a Expression in Adipose Tissue of Obese Mice
Because IL-1a is elevated in obese mice serum and affects lipid
content, we next wished to characterize where the IL-1a is mainly
expressed and whether the IL-1a was differentially expressed in
lean and HFD-induced obese mice. We first assessed the tissue
specific expression pattern of IL-1a by means of real-time
quantitative PCR. Although IL-1a mRNA was expressed in
epididymal and subcutaneous white adipose tissue (EWAT and
SWAT, respectively), as well as brown adipose tissue (BAT), it was
mainly expressed in the liver and spleen (Fig. 4A and 4B). When
Figure 3. Effect of IL-1a administration on lipids levels. (A–C) Serum total cholesterol (TC), triglyceride (TG), and LDL levels in IL-1a
administered mice. IL-1a (10 mg/kg body weight) or vehicle (normal saline) was administered IP respectively. At 0, 4, 12, and 24 hours after IL-1a or
vehicle injection, blood samples were collected and levels of TC, TG, LDL cholesterol were determined using the colorimetric enzymatic method and
an autoanalyzer. (D) Liver triglyceride content in IL-1a administered mice. IL-1a (10 mg/kg body weight) or vehicle (normal saline) was administered IP
respectively. At 0, 4, 12, and 24 hours after IL-1a or vehicle injection, livers were collected and lipids were extracted from the livers. Levels of
triglyceride were determined using the colorimetric enzymatic method and an autoanalyzer. Values represent means 6 S.E.M. (n=6). *P,0.05 as
compared to the vehicle injection group.
doi:10.1371/journal.pone.0029524.g003
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expressed lower amounts of IL-1a (Fig. 4A). Because IL-1 Ra is a
natural antagonist that is specific to IL-1 [23], the presence of IL-
1Ra mRNA was measured in the tissues of lean and HFD-induced
obese mice. IL-1Ra transcript was expressed in the liver, EWAT,
SWAT, BAT, and spleen (Fig. 4C and 4D). In contrast to IL-1a,
IL-1Ra was significantly higher in the livers of obese mice as
compared to lean mice (Fig. 4D), but it was lower in SWAT of
obese mice as compared to lean mice (Fig. 4C).
Adipocyte Differentiation
Since IL-1a is correlated with obesity in the in vivo study, we
wished to determine if IL-1a affected the differentiation process of
adipocytes. The differentiating 3T3-L1 cells were cultured in the
absence or 1 ng/ml, 10 ng/ml, and 100 ng/ml of IL-1a for 8
days. At day 8, the differentiation was terminated and cells were
detected by Oil Red O staining. Untreated differentiated cells had
many lipid droplets indicating lipid accumulation. However, lipid
accumulation was inhibited by IL-1a treatment in a dose
dependent manner (Fig. 5A). This observation was further
supported by the quantitative analysis of neutral lipid content by
measuring the absorbance at 500 nm (Fig. 5B). Untreated
differentiated 3T3L1 cells showed higher levels of lipid staining
with the Oil Red O dye, which was significantly reduced by higher
doses of IL-1a (10 ng/ml and 100 ng/ml) treatment (Fig. 5B).
To identify the mechanism of the inhibition of adipocyte
differentiation by IL-1a, the expression of peroxisome proliferator-
activated receptor gamma (PPAR-c), a key transcriptional factor
for adipocytes differentiation, was examined. The mRNA and
protein expressions of PPAR-c were significantly inhibited by IL-
1a treatment in 3T3-L1 differentiating adipocytes in a dose
dependent manner (Fig. 6A and 6B). We further examined the
effect of IL-1a on adiponectin and IL-6 production in 3T3-L1
differentiating adipocytes. Adiponectin secretion was suppressed
by IL-1a treatment of 1 ng/ml, 10 ng/ml, and 100 ng/ml
(Fig. 6C). In contrast, IL-6 production was increased by IL-1a
treatment in a dose dependent manner (Fig. 6D).
Discussion
In this study, we found that both IL-1a polymorphisms
C2889T (rs1800587) and G+4845T (rs17561) were associated
with an increase in BMI in obese healthy women. In addition, we
demonstrated that the polymorphism of rs1800587 affected the
transcriptional activity of IL-1a in pre-adipocyte 3T3-L1 cells. We
extended these observations in vivo to an HFD-induced obese
Figure 4. Expression of IL-1a and IL-1Ra in adipose tissue from high-fat diet-induced obese mouse models. Levels of IL-1a mRNA (A
and B) and IL-1 Ra mRNA (C and D) were determined by quantitative real-time PCR. Experiments were performed in triplicate and values represent
means 6 S.E.M. (n=3). IL-1a and IL-1Ra expression levels were normalized to HPRT levels. EWAT: Epididymal White Adipose Tissue; SWAT:
Subcutaneous White Adipose Tissue; BAT: Brown Adipose Tissue.
doi:10.1371/journal.pone.0029524.g004
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findings imply IL-1a may have a critical function in the
development of obesity in humans.
In a previous study, we reported an association between the
polymorphism in the IL-1b gene and obesity in women. A
significant decrease was found for the IL-1b T allele in an
overweight group compared to a lean group [19]. In this study, an
apparent association between the IL-1a polymorphisms
(rs1800587 and rs17561) and BMI in women was found.
Additionally, to investigate whether the observed association has
any physiological (pathophysiological) relevance, the plasma IL-1a
levels were measured in the four BMI subgroups. As expected,
circulating IL-1a concentrations tended to be higher in the
overweight groups than in the lean group, but not significantly so.
We also measured the plasma CRP concentrations in the four
groups. CRP is a primitive acute-phase inflammatory protein that
is released in response to acute injury, infection, or other
inflammatory stimuli, such as hypersensitivity reactions, inflam-
matory diseases, allograft rejection, malignancy, necrosis, and
trauma [24]. Synthesis of CRP occurs in hepatocytes and is
regulated primarily by IL-1a, as well as IL-6 and TNF-a [25,26].
CRP levels are also reported to associate positively with BMI,
suggesting that CRP is a useful biomarker for obesity-linked
chronic inflammatory states [27–29]. As expected, the CRP levels
were significantly higher in the overweight groups than in the lean
group in this study. However, no association between the genotype
of IL-1a -889C/T and the levels of plasma CRP was found (data
not shown).
The mechanism by which IL-1a gene polymorphisms influence
BMI is unknown. Previous studies have shown that IL-1a
production by cultured peripheral blood mononuclear cells in an
obese group was significantly higher than in a control group [12]
and that healthy non-obese donors with the IL-1a –889TT
genotype had increased levels of IL-1a production [16]. Wei et al.
[30] also reported that C/T conversion increases the activity of the
IL-1a promoter in the human astrocyte cell line. Additionally,
several studies have reported that chronic inflammatory diseases
including rheumatoid arthritis, Alzheimer disease, and periodon-
Figure 5. IL-1a inhibits differentiation of preadipocytes. (A) The differentiating 3T3-L1 cells were treated with IL-1a at various concentrations
for 8 days. Intracellular lipids accumulation was monitored by Oil Red O staining. After staining, dishes were photographed and quantified. (B)T o
estimate the extent of adipose conversion, isopropanol was added to the plate. Optical density was measured at 500 nm using an automated
microplate ELISA reader. Values are mean 6 S.E.M. of three independent experiments. *P,0.05 compared with untreated and differentiated cells. Ins:
Insulin; Dex: Dexamethasone; Ibmx: 3-isobutyl-1-methylxanthine.
doi:10.1371/journal.pone.0029524.g005
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polymorphism [31–34]. Thus, it was expected that the T allele
carriers might show a higher BMI. However, contrary to all
expectations, this study showed an association between the T allele
and a lower BMI value. The possible explanations for these
discrepancies are not clear. Any effect of this polymorphism on
obesity could be influenced by interactions with the ethnic
background and other genetic or environmental factors that
influence the study population. In addition, to determine the
functional significance of the C/T variant in adipocytes,
transcription levels from reporter gene constructs containing the
–889C/T polymorphism in the IL-1a regulatory region were
compared in this study. In vitro studies comparing the –889C and
–889T promoters demonstrated decreased transcription from the
–889T promoter in 3T3L-1 adipocytes.
To examine whether the IL-1a is correlated with obesity in vivo,
we measured the levels of IL-1a from serum of HFD-induced
obese mice. As shown in Fig. 2, IL-1a levels were higher in HFD-
induced obese mice than in lean mice. We next examined the
effects of IP administration of IL-1a to mice. We showed that IP
administration of IL-1a to mice increased blood levels of TG at
12 hours after injection. Although there is little research on the
effects of administration of IL-1a, Janik et al. [35] reported that IV
administration of IL-1a to patients with cancer stimulates leptin
production in a dose dependent fashion.
There have been no reports on the effects of obesity on the
adipose tissue content of IL-1a. To determine where IL-1a is
mainly expressed and whether IL-1a was differentially expressed
in lean and obese mice, we measured the expression levels of IL-1a
in WAT adipose tissue. As shown in Figs. 4A and 4B, IL-1a
mRNA was mainly expressed in the liver and spleen, as well as in
EWAT, SWAT, and BAT. When compared to that of lean mice,
the EWAT and SWAT from obese mice expressed lower amounts
of IL-1a. We also observed that the transcript of IL-1 Ra, a
natural antagonist that is specific to IL-1, was expressed in the
liver, EWAT, SWAT, BAT, and spleen (Figs. 4C and 4D). In
Figure 6. IL-1a inhibits PPAR-c and adiponectin (but not IL-6) in 3T3-L1 cells. The differentiating 3T3-L1 cells were cultured in the absence
or 1 ng/ml, 10 ng/ml, and 100 ng/ml of IL-1a for 8 days. (A) Levels of PPAR-c mRNA were determined by quantitative real-time PCR. PPAR-c
expression levels were normalized to HPRT levels. Experiments were performed in triplicate, and values represent means 6 S.E.M. (B) The protein
expression of PPAR-c was examined by western blot analysis. Protein levels were quantified by densitometry. Values are mean 6 S.E.M. of three
independent experiments and are expressed as a percentage relative to the control (100%). (C) Adiponectin and (D) IL-6 productions were examined
by ELISA method. Experiments were performed in duplicate and values are mean 6 S.E.M. of three independent experiments. *P,0.05 compared
with untreated and differentiated cells. Ins: Insulin; Dex: Dexamethasone; Ibmx: 3-isobutyl-1-methylxanthine.
doi:10.1371/journal.pone.0029524.g006
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obese mice than in those of lean mice (Fig. 4D). These data are
consistent with work by Juge-Aubry et al. [36], showing that when
compared to the tissues of lean mice, most tissues from obese
animals expressed higher amounts of IL-1Ra, with a 37- and 5-
fold increase in EWAT and inguinal WAT (IWAT) from obese
mice, respectively. They also showed that in contrast with IL-1Ra,
IL-1b mRNA in IWAT was lower in obese animals than in lean
mice. Based on these findings, it may be explained by the auto-
and paracrine effects of the increased IL-1Ra:IL-1a ratio.
We next tested whether IL-1a affects the differentiation process
of preadipocytes. In 3T3-L1 differentiating adipocytes, IL-1a
inhibited the differentiation programme, as shown by the
decreased levels of PPAR-c (Fig. 5 and Fig. 6). In addition, IL-
1a treatment inhibited adiponectin secretion but enhanced IL-6
production in a dose dependent manner (Fig. 6). Mra ´cek et al. [37]
reported that IL-1b and LPS (but not IL-6) inhibited differenti-
ation and downregulated PPAR-c in brown adipocytes. The
circulating adiponectin level is an index of insulin sensitivity. It has
been shown that IL-1b strongly attenuated adiponectin expression
and secretion in both differentiating 3T3-F442A cells and fully
differentiated 3T3-L1 adipocytes [38]. Uno et al. [39] reported
that long-term IL-1a treatment enhanced IL-6 production in 3T3-
L1 adipocytes. IL-1a and IL-1b bind to the same receptors and
exert similar biological activities via the activation of similar
signaling pathways [40]. However, IL-1a and IL-1b differ
dramatically in the sub-cellular compartments in which they are
active [41–43]. Compared with a number of reports on the role of
IL-1b as an endogenous mediator of insulin resistance, studies on
the relationship between IL-1a and insulin signaling and obesity
are rare.
The role of IL-1a in obesity has not been studied yet, and there
are no studies that examine the effect of IL-1a in both in vivo and
in vitro. In addition, there are no studies that perform the
functional analyses of specific genes of interest resulting from the
study of human polymorphism. To delineate the specific role of
IL-1a in obesity, we found an apparent association between IL-1a
polymorphisms (rs1800587 and rs17561) and BMI in obese
women and the effect of the IL-1a variant on transcriptional
activity. We further studied this observation in vivo with an HFD-
induced obese mouse model and in vitro with 3T3-L1 adipocytes.
In the obese mouse model, IL-1a levels were higher in obese mice
than in lean mice. In agreement with our results, the work in
humans demonstrated that the plasma concentrations of IL-1a
and IL-1b were significantly higher in obese women than in non-
obese subjects, and the IL-1a levels were correlated with the fat
mass% [11]. In addition, triglyceride was increased 12 hours after
exogenous IL-1a administration. Paradoxically, IL-1a treatment
attenuated the differentiation of preadipocytes through suppres-
sion of PPAR-c and lipid accumulation. A hypothesis to reconcile
this unexpected observation is that IL-1a is a homeostatic
regulator that opposes excess positive energy balance, wherein
elevated IL-1a levels in obesity reflect inadequate compensation,
analogous to what occurs with the adipokine leptin. Meanwhile,
IL-1a treatment increased IL-6 production. Elevated levels of
cytokine could prevent differentiation of preadipocytes to mature
cells and simultaneously promote their ability to produce IL-6,
which could further contribute to the systemic levels of the
cytokine. Our findings imply IL-1a may have a critical function in
the development of obesity in humans. We also suggest that
further studies should attempt to identify the detailed mechanism
for how IL-1alpha-mediated inhibition of adipocyte differentiation
and lipid accumulation would contribute to obesity.
Supporting Information
Table S1 Frequencies for IL-1a genotypes according to
PBF in females.
(DOCX)
Table S2 Frequencies for IL-1a genotypes according to
WHR in females.
(DOCX)
Author Contributions
Conceived and designed the experiments: JYU SHH. Performed the
experiments: JYU HKR SJK HLK. Analyzed the data: JYU HKR.
Contributed reagents/materials/analysis tools: JYU HKR HLK SJK.
Wrote the paper: JYU.
References
1. Miranda PJ, Defronzo RA, Califf RM, Guyton JR (2005) Metabolic syndrome:
Definition, pathophysiology, and mechanisms. Am Heart J 149(1): 33–45.
2. Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in
adipose tissue. J Clin Invest 112(12): 1785–1788.
3. Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, et al. (2006)
Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin
resistance in primary cultures of newly differentiated human adipocytes.
Endocrinology 147(11): 5340–5351.
4. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, et al. (1999) Evidence
for a link between adipose tissue interleukin-6 content and serum C-reactive
protein concentrations in obese subjects. Circulation 99(16): 2221–2222.
5. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, et al. (2004) Circulating
mononuclear cells in the obese are in a proinflammatory state. Circulation 2004
110(12): 1564–1571.
6. He J, Usui I, Ishizuka K, Kanatani Y, Hiratani K, et al. (2006) Interleukin-
1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-
1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol 20(1): 114–124.
7. Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1
receptor antagonist. Int Rev Immunol 16(5–6): 457–499.
8. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA, Jr. (1984)
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of
procoagulant activity in human vascular endothelial cells. J Exp Med 160(2):
618–623.
9. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA (1986) Inducible
interleukin-1 gene expression in human vascular smooth muscle cells. J Clin
Invest 78(6): 1432–1438.
10. Dinarello CA, Wolff SM (1993) The role of interleukin-1 in disease. N Engl J Med
328(2): 106–113.
11. Di Renzo L, Bigioni M, Del Gobbo V, Premrov MG, Barbini U, et al. (2007)
Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight
obese syndrome: relationship to body composition and IL-1 alpha and beta
plasma levels. Pharmacol Res 55(2): 131–138.
12. Raymond NC, Dysken M, Bettin K, Eckert ED, Crow SJ, et al. (2000) Cytokine
production in patients with anorexia nervosa, bulimia nervosa, and obesity.
Int J Eat Disord 28(3): 293–302.
13. Salmenniemi U, Ruotsalainen E, Pihlajama ¨ k iJ ,V a u h k o n e nI ,
Kainulainen S, et al. (2004) Multiple abnormalities in glucose and energy
metabolism and coordinated changes in levels of adiponectin, cytokines,
and adhesion molecules in subjects with metabolic syndrome. Circulation
110(25): 3842–3848.
14. Spranger J, Kroke A, Mo ¨hlig M, Hoffmann K, Bergmann MM, et al. (2003)
Inflammatory cytokines and the risk to develop type 2 diabetes: results of the
prospective population-based European Prospective Investigation into Cancer
and Nutrition (EPIC)-Potsdam Study. Diabetes 52(3): 812–817.
15. Lennard A, Gorman P, Carrier M, Griffiths S, Scotney H, et al. (1992) Cloning
and chromosome mapping of the human interleukin-1 receptor antagonist gene.
Cytokine 4(2): 83–89.
16. Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, et al. (2002)
Cloning and functional analysis of the allelic polymorphism in the transcription
regulatory region of interleukin 1-a. Immunogenetics 54(2): 82–86.
17. Kawaguchi Y, Tochimoto A, Hara M, Kawamoto M, Sugiura T, et al. (2007)
Contribution of single nucleotide polymorphisms of the IL1A gene to the
cleavage of precursor IL-1alpha and its transcription activity. Immunogenetics
59(6): 441–448.
18. Sweeting HN (2007) Measurement and definitions of obesity in childhood and
adolescence: a field guide for the uninitiated. Nutr J 6: 32.
IL-1a Functional Variant and Obesity
PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e2952419. Um JY, Chung HS, Song MY, Shin HD, Kim HM (2004) Association of
interleukin-1beta gene polymorphism with body mass index in women. Clin
Chem 50(3): 647–650.
20. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, et al. (2000) An IL 6
promoter polymorphism is associated with a lifetime risk of development of
Kaposi sarcoma in men infected with human immunodeficiency virus. Blood
96(7): 2562–2567.
21. Tai H, Endo M, Shimada Y, Gou E, Orima K, et al. (2002) Association of
interleukin-1 receptor antagonist gene polymorphisms with early onset
periodontitis in Japanese. J Clin Periodontol 29(10): 882–888.
22. Folch J, Lees M, Sloane Stanly GH (1957) A simple method for isolation and
purification of total lipids from animal tissues. J Biol Chem 226(1): 497–509.
23. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM (1987) Specific interleukin-1
inhibitor in serum and urine of children with systemic juvenile chronic arthritis.
Lancet 2(8570): 1240–1242.
24. Du Clos TW (2000) Function of C-reactive protein. Ann Med 32(4): 274–278.
25. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, et al. (1991) Tumor
necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis
of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of
human hepatocytes. Biochim Biophys Acta 1091(3): 405–408.
26. Misra A (2004) C-reactive protein in young individuals: problems and
implications for Asian Indians. Nutrition 20(5): 478–481.
27. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC (1996) C reactive
protein and its relation to cardiovascular risk factors: a population based cross
sectional study. BMJ 312(7038): 1061–1065.
28. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in
healthy subjects: associations with obesity, insulin resistance, and endothelial
dysfunction: a potential role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol 19(4): 972–978.
29. Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin
Chim Acta 380(1–2): 24–30.
30. Wei X, Chen X, Fontanilla C, Zhao L, Liang Z, et al. (2007) C/T conversion
alters interleukin-1A promoter function in a human astrocyte cell line. Life Sci
80(12): 1152–1156.
31. McDowell TL, Symons JA, Ploski R, Førre O, Duff GW (1995) A genetic
association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha
polymorphism. Arthritis Rheum 38(2): 221–228.
32. Rainero I, Bo M, Ferrero M, Valfre ` W, Vaula G, et al. (2004) Association
between the interleukin-1alpha gene and Alzheimer’s disease: a meta-analysis.
Neurobiol Aging 25(10): 1293–1298.
33. Sciacca FL, Ferri C, Licastro F, Veglia F, Biunno I, et al. (2003) Interleukin-1B
polymorphism is associated with age at onset of Alzheimer’s disease. Neurobiol
Aging 24(7): 927–931.
34. Moreira PR, Costa JE, Gomez RS, Gollob KJ, Dutra WO (2007) The IL1A
(–889) gene polymorphism is associated with chronic periodontal disease in a
sample of Brazilian individuals. J Periodontal Res 42(1): 23–30.
35. Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, et al. (1997)
Interleukin 1 alpha increases serum leptin concentrations in humans. J Clin
Endocrinol Metab 82(9): 3084–3086.
36. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, et al. (2003)
Adipose tissue is a major source of interleukin-1 receptor antagonist:
upregulation in obesity and inflammation. Diabetes 52(5): 1104–1110.
37. Mra ´cek T, Cannon B, Houstek J (2004) IL-1 and LPS but not IL-6 inhibit
differentiation and downregulate PPAR gamma in brown adipocytes. Cytokine
26(1): 9–15.
38. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange ´A ,e t
al. (2006) Long-term treatment with interleukin-1beta induces insulin resistance
in murine and human adipocytes. Diabetologia 49(9): 2162–2173.
39. Uno T, He J, Usui I, Kanatani Y, Bukhari A, et al. (2008) Long-term
interleukin-1alpha treatment inhibits insulin signaling via IL-6 production and
SOCS3 expression in 3T3-L1 adipocytes. Horm Metab Res 40(1): 8–12.
40. Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, et al. (2007)
Differential role and tissue specificity of interleukin-1alpha gene expression in
atherogenesis and lipid metabolism. Atherosclerosis 195(1): 31–38.
41. Fantuzzi G, Zheng H, Faggioni R, Benigni F, Ghezzi P, et al. (1996) Effect of
endotoxin in IL-1 beta-deficient mice. J Immunol 157(1): 291–296.
42. Wilasrusmee C, Da Silva M, Singh B, Kittur S, Siddiqui J, et al. (2002) A new in
vitro model to study endothelial injury. J Surg Res 104(2): 131–136.
43. Braddock M, Quinn A (2004) Targeting IL-1 in inflammatory disease: new
opportunities for therapeutic intervention. Nat Rev Drug Discov 3(4): 330–339.
IL-1a Functional Variant and Obesity
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29524